Repurposing Venetoclax and Glofitamab to Improve Patient Response in Mantle Cell Lymphoma
Principal Investigator: Dr. Tycel Phillips
Disease: Mantle cell lymphoma
Research Description: Mantle cell lymphoma (MCL) is a rare form of non-Hodgkin lymphoma (NHL) that is diagnosed mostly in older male patients. Symptoms of this cancer can include fever, night sweats, abdominal pain, anemia, thrombocytopenia, itchy skin, rashes, lymph node inflammation and a painfully enlarged spleen. Currently there is no ‘best’ treatment for patients who are diagnosed with MCL, and treatment responses vary among patients. Most treatments include chemotherapy, and these drugs have toxic side effects that can lead to complications including infection, heart failure, renal failure and potentially death, especially in older patients. This Phase II clinical trial will combine a drug already approved to treat MCL (lenalidomide) with two other drugs approved for other blood cancers (venetoclax and glofitamab) to improve outcomes in all patients diagnosed with MCL, irrespective of age, medical conditions, and disease related risk factors. This study could lead to a standardized treatment regimen that is safe and tolerable enough for all MCL patients, potentially eliminating the need for high dose chemotherapy and improving overall patient outcomes.
Funding Partner: Goldman Philanthropic Partnerships
CWR Funding Role: Participating funder